Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Graham Mann on Genetic Mutations in Different Types of Melanoma

November 9th 2016

Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.

IDO Inhibitors for Melanoma

October 31st 2016

Emerging Immunotherapy Combinations for Melanoma

October 31st 2016

Looking to the Future of Melanoma

October 31st 2016

Sequencing Strategies for Recurrent/Refractory Melanoma

October 31st 2016

Treatment Beyond Melanoma Progression

October 31st 2016

Abscopal Effect and Pseudoprogression in Melanoma

October 31st 2016

Single vs Dual Checkpoint Inhibition in Melanoma

October 31st 2016

Questions About Sequencing in BRAF-Mutant Melanoma

October 31st 2016

Dual-Targeted Therapy for BRAF-Mutant Melanoma

October 31st 2016

Risk Stratification for Advanced Melanoma

October 31st 2016

Neoadjuvant Therapy for Melanoma

October 31st 2016

Adjuvant PD-(L)1 Inhibitors for Melanoma

October 31st 2016

Adjuvant Therapy for Melanoma

October 31st 2016

Surgical Management of Locoregional Melanoma

October 31st 2016

James Allison Says Rational Combinations Key to Immunotherapy Success in "Cold" Tumors

October 31st 2016

Immunotherapy has been a game changer in oncology, improving survival and providing long, durable responses in melanoma, lung, head and neck cancer, and others.

Active Surveillance a Valued Approach for Early Prostate Cancer

October 28th 2016

Before undergoing surgery, radiation therapy, or a systemic treatment, Clayton S. Lau, MD, advises that the active surveillance approach for some patients with early prostate cancer is likely a more effective approach—but they should be better educated on it.

Dr. Saenger on the Importance of Biomarkers When Administering Immunotherapy

October 27th 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses the importance of developing accurate biomarkers when it comes to administering immunotherapy.

Immunotherapy Potentially Promising for Treatment of ATC

October 21st 2016

Given the poor prognoses often seen in patients with anaplastic thyroid cancer, researchers are seeking novel therapies that may hold more promise than surgery or radiation.

Dr. Rimm on Biomarker Testing in Lung Cancer

October 19th 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses various options for biomarker testing in lung cancer.